Predictors of clozapine response in patients with treatment-refractory schizophrenia: Results from a danish register study

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 678-683

  Nielsen, Jimmi ^a,b   Nielsen, Rene Ernst ^a   Correll, Christoph U ^c,d  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b Maximum Security Unit   (Denmark)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

algorithm; antipsychotic; bed days; clozapine; hospitalization; mirror image; schizophrenia; time to admission; Treatment resistant

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OUTCOME ASSESSMENT; OUTPATIENT CARE; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT RESPONSE;

ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DATABASES, FACTUAL; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SCHIZOPHRENIA; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865865840     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318267b3cd     Document Type: Review

References (35)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
2. Gerlach J, Koppelhus P, Helweg E, et al. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand. 1974;50:410-424.
3. Conley RR, Kelly DL, Richardson CM, et al. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol. 2003;23:668-671.
4. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-610.
5. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91.
6. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999;175:576-580.
7. Nielsen J, Foldager L, Meyer JM. Increased use of antibiotics in patients treated with clozapine. Eur Neuropsychopharmacol. 2009;19:483-486.
8. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 2012;38(3):592-598.
9. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother. 2007;7:829-839.
10. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66:1116-1121.
11. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71-93.
12. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68:1751-1762.
13. Nielsen J, le Quach P, Emborg C, et al. 10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand. 2010;122:356-366.
14. Nielsen J, Dahm M, Lublin H, et al. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24:965-971.
15. Umbricht DS, Wirshing WC, Wirshing DA, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry. 2002;63:420-424.
16. Lieberman JA, Kane JM, Safferman AZ, et al. Predictors of response to clozapine. J Clin Psychiatry. 1994;55(suppl B):126-128.
17. Szymanski S, Lieberman J, Pollack S, et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry. 1996;39:249-254.
18. Semiz UB, Cetin M, Basoglu C, et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1330-1336.
19. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry. 1994;55:44-49.
20. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663-667.
21. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004;30:193-217.
22. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol. 2007;22:249-267.
23. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(suppl 9):5-9.
24. Kyriakopoulos M, Frangou S. Pathophysiology of early onset schizophrenia. Int Rev Psychiatry. 2007;19:315-324.
25. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008;34:60-71.
26. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63:721-730.
27. Pollack S, Woerner MG, Howard A, et al. Clozapine reduces rehospitalization among schizophrenia patients. Psychopharmacol Bull. 1998;34:89-92.
28. Ahn YM, Chang JS, Kim Y, et al. Reduction in hospital stay of chronic schizophrenic patients after long-term clozapine treatment. Int Clin Psychopharmacol. 2005;20:157-161.
29. Hayhurst KP, Brown P, Lewis SW. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. J Psychopharmacol. 2002;16:169-175.
30. Ghaemi SN, Ziegler DM, Peachey TJ, et al. Cost-effectiveness of clozapine therapy for severe psychosis. Psychiatr Serv. 1998;49:829-831.
31. Rosenheck R, Cramer J, Allan E, et al. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Arch Gen Psychiatry. 1999;56:565-572.
32. Roy MA, Merette C, Maziade M. Subtyping schizophrenia according to outcome or severity: a search for homogeneous subgroups. Schizophr Bull. 2001;27:115-138.
33. Usall J, Suarez D, Haro JM. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res. 2007;153:225-231.
34. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003;64:30-34.
35. Correll CU, Hauser M, Auther AM, et al. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry. 2010;51:390-431.